JP2014505463A5 - - Google Patents

Download PDF

Info

Publication number
JP2014505463A5
JP2014505463A5 JP2013538829A JP2013538829A JP2014505463A5 JP 2014505463 A5 JP2014505463 A5 JP 2014505463A5 JP 2013538829 A JP2013538829 A JP 2013538829A JP 2013538829 A JP2013538829 A JP 2013538829A JP 2014505463 A5 JP2014505463 A5 JP 2014505463A5
Authority
JP
Japan
Prior art keywords
antibody
seq
cysteine
cysteines
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013538829A
Other languages
English (en)
Japanese (ja)
Other versions
JP6014596B2 (ja
JP2014505463A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/059775 external-priority patent/WO2012064733A2/en
Publication of JP2014505463A publication Critical patent/JP2014505463A/ja
Publication of JP2014505463A5 publication Critical patent/JP2014505463A5/ja
Application granted granted Critical
Publication of JP6014596B2 publication Critical patent/JP6014596B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013538829A 2010-11-09 2011-11-08 均一コンジュゲーションのための抗体足場 Expired - Fee Related JP6014596B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41158810P 2010-11-09 2010-11-09
US61/411,588 2010-11-09
PCT/US2011/059775 WO2012064733A2 (en) 2010-11-09 2011-11-08 Antibody scaffold for homogenous conjugation

Publications (3)

Publication Number Publication Date
JP2014505463A JP2014505463A (ja) 2014-03-06
JP2014505463A5 true JP2014505463A5 (https=) 2014-12-25
JP6014596B2 JP6014596B2 (ja) 2016-10-25

Family

ID=46051511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013538829A Expired - Fee Related JP6014596B2 (ja) 2010-11-09 2011-11-08 均一コンジュゲーションのための抗体足場

Country Status (4)

Country Link
US (2) US20130330350A1 (https=)
EP (1) EP2638066A4 (https=)
JP (1) JP6014596B2 (https=)
WO (1) WO2012064733A2 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
JP6411218B2 (ja) 2012-02-15 2018-10-24 ノヴォ ノルディスク アー／エス 骨髄細胞で発現されるトリガー受容体１（ｔｒｅｍ−１）に結合し、それを遮断する抗体
CN104203977A (zh) 2012-02-15 2014-12-10 诺和诺德A/S（股份有限公司） 结合肽聚糖识别蛋白1的抗体
US9700638B2 (en) 2012-05-08 2017-07-11 Rutgers, The State University Of New Jersey Near infrared label and methods of use thereof
WO2014182927A1 (en) * 2013-05-08 2014-11-13 Rutgers, The State University Of New Jersey Near infrared label and methods of use thereof
EP2953976B1 (en) * 2013-02-08 2021-03-24 Novartis Ag Specific sites for modifying antibodies to make immunoconjugates
RU2652880C2 (ru) * 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
PL2991683T3 (pl) 2013-05-02 2020-03-31 Glykos Finland Oy Koniugaty glikoproteiny lub glikanu z toksycznym ładunkiem
SG11201601424PA (en) 2013-08-28 2016-03-30 Stemcentrx Inc Site-specific antibody conjugation methods and compositions
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
WO2015048312A1 (en) 2013-09-26 2015-04-02 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
SG11201604664PA (en) 2013-12-12 2016-07-28 Stemcentrx Inc Novel anti-dpep3 antibodies and methods of use
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
IL310627B2 (en) 2014-01-31 2026-04-01 Daiichi Sankyo Co Ltd Anti-HER2 antibody-drug conjugates, compositions containing them and uses thereof
KR20230088389A (ko) 2014-02-11 2023-06-19 씨젠 인크. 단백질의 선택적 환원
CA2939941A1 (en) 2014-02-21 2015-08-27 Abbvie Stemcentrx Llc Anti-dll3 antibodies and drug conjugates for use in melanoma
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
KR102445502B1 (ko) * 2014-04-10 2022-09-21 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
EA037844B1 (ru) 2014-07-17 2021-05-27 Ново Нордиск А/С Сайт-направленный мутагенез антител к trem-1
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CA2974511A1 (en) * 2015-01-22 2016-07-28 Prothena Biosciences Limited Antibodies recognizing medin
GB201506399D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506394D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506402D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506407D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
HRP20211058T8 (hr) 2015-07-29 2021-11-26 Novartis Ag Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
CN109843327B (zh) 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11273155B2 (en) 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
JP6679762B2 (ja) 2017-01-17 2020-04-15 第一三共株式会社 抗ｇｐｒ２０抗体及び抗ｇｐｒ２０抗体−薬物コンジュゲート
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
JP7148524B2 (ja) * 2017-02-08 2022-10-05 ファイザー・インク キャップされたおよびキャップされていない抗体システインのための大規模産生プロセス、ならびに治療的タンパク質コンジュゲーションにおけるその使用
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CN117982673A (zh) 2017-02-28 2024-05-07 第一三共株式会社 抗her3抗体-药物偶联物的应用
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
TW202532104A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
IL324591A (en) 2017-08-31 2026-01-01 Daiichi Sankyo Co Ltd Improved antibody-drug conjugate production methods
CA3074208C (en) 2017-08-31 2023-10-03 Daiichi Sankyo Company, Limited Novel method for producing antibody-drug conjugate
CN111417409B (zh) 2017-11-14 2022-07-08 麦迪穆有限责任公司 吡咯并苯并二氮杂䓬缀合物
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
WO2019195126A1 (en) 2018-04-02 2019-10-10 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CN108642176B (zh) * 2018-04-12 2021-11-09 江门市中心医院 Part1作为乳腺癌诊断、治疗以及预后标志物的应用
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
US20210283141A1 (en) 2018-05-25 2021-09-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
CA3108044A1 (en) 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
WO2020059772A1 (ja) 2018-09-20 2020-03-26 第一三共株式会社 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CN110596387B (zh) * 2019-09-20 2020-06-12 四川大学华西医院 Cox10自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
US20230241259A1 (en) * 2020-06-10 2023-08-03 Memorial Sloan Kettering Cancer Center IMAGING COMPOUNDS SELECTIVE FOR NaV1.7
GB202105186D0 (en) 2021-04-12 2021-05-26 Medimmune Ltd Pyrrolobenzodiazepine conjugates
CN117285647A (zh) * 2022-06-17 2023-12-26 南京北恒生物科技有限公司 靶向ccr8的嵌合抗原受体及其用途
EP4721766A1 (en) 2023-06-02 2026-04-08 Daiichi Sankyo Company, Limited Combination of (anti-her3 antibody)-drug conjugate and rasg12c inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018809B1 (en) * 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
DK1791565T3 (en) * 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
WO2008145140A2 (en) * 2007-05-31 2008-12-04 Genmab A/S Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals
BRPI0907046A2 (pt) * 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo

Similar Documents

Publication Publication Date Title
JP2014505463A5 (https=)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
MX357193B (es) Moleculas de union anti-alfa sinucleina.
RU2016151265A (ru) Антитела, направленные на cd127
EP2826791A3 (en) Humanized anti-C5aR antibodies
WO2011110642A3 (en) Monoclonal antibodies against c-met
UA118332C2 (uk) Білок, що зв'язує антиген cd27l
SI2771031T1 (en) Humanized antibodies that recognize alpha-synuclein
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
RU2019119442A (ru) Новый коньюгат аманитина
RU2017102193A (ru) Конструкции полиспецифических антител
EA201100923A1 (ru) Антитела человека против тканевого фактора
UA115122C2 (uk) Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини і cd3, що не є людським
IN2014CN03936A (https=)
JP2014519524A5 (https=)
JP2016527314A5 (https=)
EP3539988A3 (en) Monoclonal antibodies against her2
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
EP3839049A3 (en) Antibodies, variable domains & chains tailored for human use
RU2016101711A (ru) Высокостабильный т-клеточный рецептор и способ его получения и применения
EA201291067A1 (ru) Гуманизированные антигенсвязывающие белки к миостатину
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo